Table 1 Selected studies on targeted therapy combined with chemotherapy for T-ALL from 2022 ASH annual meeting

Authors (references)

Goekbuget et al. [4]

Hatta et al. [5]

Shimony et al. [6]

Suo et al. [11]

Yu et al. [12]

Study agents

Nelarabine + cyclophosphamide

Nelarabine + L-ASP

Nelarabine monotherapy vs combination

Venetoclax + HAG

Venetoclax + HAG

Analysis

N/A

II

Retrospective

N/A

II

NCT No

NCT02881086

N/A

N/A

N/A

N/A

Study period

N/A

2011–2017

2006–2021

N/A

2021–2022

Age range, years

18–55

15–24

2–69

N/A

15–60

No. of patients

281 (208 T-ALL; 73 T-LBL)

62

44 (29 combination; 15 monotherapy)

7 (3 R/R ETP-ALL; 4 newly diagnosed)

7

MRD analysis used to assign risk/postremission therapy

Yes

Yes (< 10^–3)

Yes

No

Yes (< 0.01%)

Outcome measure

1-year OS, 3-year OS, OS for SCT

3-year EFS, 3-year OS, 3-year CIR

CR, RFS, OS

CR/CRi rate

CR/CRi rate

Survival outcome

1-year OS: 89%; 3-year OS: 78%

3-year EFS: 88.6%; 3-year OS: 93.4%; 3-year CIR: 5.3%

CR: 55%; 2-year RFS: 60.5%; 2-year OS: 37.6%

CR/CRi rate: 100%

CR/CRi rate(after the first cycle): 85.7%; CR: 42.9%; CRi: 42.9%; PR: 14.3%; CR/CRi rate(after the second cycle): 100%

Summary

Early T-ALL subgroup appeared poorer outcomes

Risk stratification system in pediatric regimen was also effective for AYA patients

Nelarabine combination regimen led to better outcomes than monotherapy

V-HAG regimen in newly diagnosed and R/R ETP-ALL has led to favorable outcomes

VGHA regimen provides a new choice in the treatment of R/R ETP-ALL patients